Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenosine A2A receptors

Annual Review of Immunology

Volumn 22, Issue , 2004, Pages 657-682

  Sitkovsky, Michail V ^a   Lukashev, Dmitriy ^a   Apasov, Sergey ^a   Kojima, Hidefumi ^a   Koshiba, Masahiro ^a   Caldwell, Charles ^a   Ohta, Akio ^a   Thiel, Manfred ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Adenosine receptors; Hypoxia; Immunity; Inflammation

Indexed keywords

ADENOSINE; ADENOSINE A2 RECEPTOR; ADENOSINE RECEPTOR; CYCLIC AMP; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; OXYGEN;

B LYMPHOCYTE; CELL FUNCTION; CELL MATURATION; CELL MEDIATED CYTOTOXICITY; CELL METABOLISM; CELL PROTECTION; CELLULAR IMMUNITY; DENDRITIC CELL; DOWN REGULATION; FACTORIAL ANALYSIS; HUMAN; HYPOXIA; IMMUNE MEDIATED INJURY; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; IMMUNOPATHOLOGY; IMMUNOREGULATION; INFLAMMATION; MONONUCLEAR PHAGOCYTE; NEGATIVE FEEDBACK; NEUTROPHIL; NONHUMAN; OXIDATIVE PHOSPHORYLATION; OXYGEN TENSION; PATHOGENESIS; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; REGULATORY MECHANISM; REPORTER GENE; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; THYMOCYTE; TISSUE INJURY;

ADENOSINE; ANIMALS; ANOXIA; DNA-BINDING PROTEINS; HUMANS; IMMUNITY, CELLULAR; INFLAMMATION; NUCLEAR PROTEINS; RECEPTORS, ADENOSINE A2; SIGNAL TRANSDUCTION;

EID: 2542432162     PISSN: 07320582     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.immunol.22.012703.104731     Document Type: Review

References (120)

1. Rosenberg HF, Gallin JI. 1999. Inflammation. In Fundamental Immunology, ed. WE Paul, pp. 1151-71. Philadelphia: Lippincott, Williams and Wilkins
2. Henkart PA, Sitkovsky MV. 2003. Cytotoxic T Lymphocytes. In Fundamental Immunology, ed. WE Paul, pp. 1127-51. Philadelphia: Lippincott, Williams and Wilkins
3. Shacter E, Weitzman SA. 2002. Chronic inflammation and cancer. Oncology 16: 217-32
4. McPherson JA, Barringhaus KG, Bishop GG, Sanders JM, Rieger JM, et al. 2001. Adenosine A(2A) receptor stimulation reduces inflammation and neointimal growth in a murine carotid ligation model. Arterioscler. Thromb. Vasc. Biol. 21:791-96
5. Pockley AG. 2002. Heat shock proteins, inflammation, and cardiovascular disease. Circulation 105:1012-17
6. Shebuski RJ, Kilgore KS. 2002. Role of inflammatory mediators in thrombogenesis. J. Pharmacol. Exp. Ther. 300:729-35
7. Mulvihill NT, Foley JB. 2002. Inflammation in acute coronary syndromes. Heart 87:201-4
8. Cohen J. 2002. The immunopathogenesis of sepsis. Nature 420:885-91
9. 2A adenosine receptor as a physiological immunosuppressor and to engineer inflammation in vivo. Biochem. Pharmacol. 65:493-501
10. Webster JI, Tonelli L, Sternberg EM. 2002. Neuroendocrine regulation of immunity. Annu. Rev. Immunol. 20:125-63
11. Mellor AL, Chandler P, Lee GK, Johnson T, Keskin DB, et al. 2002. Indoleamine 2,3-dioxygenase, immunosuppression and pregnancy. J. Reprod. Immunol. 57:143-50
12. Calder PC, Grimble RF. 2002. Polyunsaturated fatty acids, inflammation and immunity. Eur. J. Clin. Nutr. 56(Suppl. 3):S14-19
13. Hellstrom I, Hellstrom KE, Pierce GE, Yang JP. 1968. Cellular and humoral immunity to different types of human neoplasms. Nature 220:1352-54
14. Rosenberg SA. 2001. Progress in human tumour immunology and immunotherapy. Nature 411:380-84
15. Ohta A, Sitkovsky M. 2001. Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature 414:916-20
16. Linden J. 2001. Molecular approach to adenosine receptors: receptor-mediated mechanisms of tissue protection. Annu. Rev. Pharmacol. Toxicol. 41:775-87
17. Fredholm BB, Ijzerman AP, Jacobson KA, Klotz K-N, Linden J. 2001. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol. Rev. 53:527-52
18. 2A receptors in downregulation of inflammation and immunity in the pathogenesis of infectious diseases. Microbes Infect. 5:515-26
19. Semenza GL. 1998. Hypoxia-inducible factor 1: master regulator of O2 homeostasis. Curr. Opin. Genet. Dev. 8:588-94
20. Semenza GL. 2000. HIF-1: Mediator of physiological and pathophysiological responses to hypoxia. J. Appl. Physiol. 88:1474-80
21. Semenza GL. 1999. Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1. Annu. Rev. Cell Dev. Biol. 15:551-78
22. Wiener CM, Booth G, Semenza GL. 1996. In vivo expression of mRNAs encoding hypoxia-inducible factor 1. Biochem. Biophys. Res. Commun. 225:485-88
23. Yu AY, Frid MG, Shimoda LA, Wiener CM, Stenmark K, Semenza GL. 1998. Temporal, spatial and oxygen-regulated expression of hypoxia-inducible factor 1 in the lung. Am. J. Physiol. Lung Cell Mol. Physiol. 275:L818-26
24. Masson N, Willam C, Maxwell PH, Pugh CW, Ratcliffe PJ. 2001. Independent function of two destruction domains in hypoxia-inducible factor-alpha chains activated by prolyl hydroxylation. EMBO J. 20:5197-206
25. Brune B, Zhou J. 2003. The role of nitric oxide (NO) in stability regulation of hypoxia inducible factor-1α (HEF-1α). Curr. Med. Chem. 10:845-55
26. Haddad JJ. 2002. Antioxidant and prooxidant mechanisms in the regulation of redox(y)-sensitive transcription factors. Cell Signal. 14:879-97
27. Jung YJ, Isaacs JS, Lee SM, Trepel J, Liu ZG, Neckers L. 2003. Hypoxia-inducible factor induction by tumour necrosis factor in normoxic cells requires receptor-interacting protein-dependent nuclear factor kappa B activation. Biochem. J. 370:1011-17
28. Haddad JJ. 2002. Recombinant human interleukin (TL)-1beta-mediated regulation of hypoxia-inducible factor-1α (HIF-1α) stabilization, nuclear translocation and activation requires an antioxidant/reactive oxygen species (ROS)-sensitive mechanism. Eur. Cytokine Netw. 13:250-60
29. Zelzer E, Levy Y, Kahana C, Shilo BZ, Rubinstein M, Cohen B. 1998. Insulin induces transcription of target genes through the hypoxia-inducible factor HIF-1α/ARNT. EMBO J. 17:5085-94
30. Jones NM, Bergeron M. 2001. Hypoxic preconditioning induces changes in HIF-1 target genes in neonatal rat brain. J. Cereb. Blood Flow Metab. 21:1105-14
31. Lukashev D, Caldwell C, Ohta A, Chen P, Sitkovsky M. 2001. Differential regulation of two alternatively spliced isoforms of hypoxia-inducible factor-1 alpha in activated T lymphocytes. J. Biol. Chem. 276:48754-63
32. Brand KA, Hermfisse U. 1997. Aerobic glycolysis by proliferating cells: a protective strategy against reactive oxygen species. FASEB J. 11:388-95
33. Valdemarsson S, Monti M. 1994. Increased ratio between anaerobic and aerobic metabolism in lymphocytes from hyperthyroid patients. Eur. J. Endocrinol. 130:276-80
34. Cheung K, Morris B. 1984. The respiration and energy metabolism of sheep lymphocytes. Aust. J. Exp. Biol. Med. Sci. 62 (Pt. 6):671-85
35. Kojima H, Gu H, Nomura S, Caldwell CC, Kobata T, et al. 2002. Abnormal B lymphocyte development and autoimmunity in hypoxia-inducible factor 1α-deficient chimeric mice. Proc. Natl. Acad. Sci. USA 99:2170-74
36. Goda N, Ryan HE, Khadivi B, McNulty W, Rickert RC, Johnson RS. 2003. Hypoxia-inducible factor 1α is essential for cell cycle arrest during hypoxia. Mol. Cell Biol. 23:359-69
37. Caldwell CC, Kojima H, Lukashev D, Armstrong J, Farber M, et al. 2001. Differential effects of physiologically relevant hypoxic conditions on T lymphocyte development and effector functions. J. Immunol. 167:6140-49
38. Fossati G, Moulding DA, Spiller DG, Moots RJ, White MR, Edwards SW. 2003. The mitochondrial network of human neutrophils: role in chemotaxis, phagocytosis, respiratory burst activation, and commitment to apoptosis. J. Immunol. 170:1964-72
39. Saadi S, Wrenshall LE, Platt JL. 2002. Regional manifestations and control of the immune system. FASEB J. 16:849-56
40. Schor H, Vaday GG, Lider O. 2000. Modulation of leukocyte behavior by an inflamed extracellular matrix. Dev. Immunol. 7:227-38
41. MacDonald HR, Koch CJ. 1977. Energy metabolism and T cell-mediated cytolysis. I. Synergism between inhibitors of respiration and glycolysis. J. Exp. Med. 146:698-709
42. Simchowitz L, Mehta J, Spilberg I. 1979. Chemotactic factor-induced generation of superoxide radicals by human neutrophils: effect of metabolic inhibitors and antiinflammatory drugs. Arthritis Rheum. 22:755-63
43. Borregaard N, Herlin T. 1982. Energy metabolism of human neutrophils during phagocytosis. J. Clin. Invest. 70:550-57
44. Cramer T, Yamanishi Y, Clausen BE, Forster I, Pawlinski R, et al. 2003. HIF-1α is essential for myeloid cell-mediated inflammation. Cell 112:645-57
45. 2A receptors and therapeutic applications. Curr. Top Med. Chem. 3:413-26
46. Rudolphi KA, Schubert P, Parkinson FE, Fredholm BB. 1992. Neuroprotective role of adenosine in cerebral ischemia. Trends Pharmacol. Sci. 13:439
47. Berne RM, Rubio R. 1974. Regulation of coronary blood flow. Adv. Cardiol. 12:303-17
48. Decking UKM, Schlieper G, Kroll K, Schrader J. 1997. Hypoxia-induced inhibition of adenosine kinase potentiates cardiac adenosine release. Circ. Res. 81:154-64
49. Synnestvedt K, Furuta GT, Comerford KM, Louis N, Karhausen J, et al. 2002. Ecto-5′-nucleotidase (CD73) regulation by hypoxia-inducible factor-1 mediates permeability changes in intestinal epithelia. J. Clin. Invest. 110:993-1002
50. Drury AN, Szent-Gyorgy A. 1929. The physiological activity of adenine compounds with special reference to their actions upon the mammalian heart. J. Physiol. 68:213-37
51. Fredholm BB. 1995. Adenosine, adenosine receptors and the actions of caffeine. Pharmacol. Toxicol. 76:93-101
52. Olah ME, Stiles GL. 1995. Adenosine receptor subtypes: characterization and therapeutic regulation. Annu. Rev. Pharmacol. Toxicol. 35:581-606
53. Salvatore CA, Tilley SL, Latour AM, Fletcher DS, Koller BH, Jacobson MA. 2000. Disruption of the A(3) adenosine receptor gene in mice and its effect on stimulated inflammatory cells. J. Biol. Chem. 275:4429-34
54. Thiel M, Chambers JD, Chouker A, Fischer S, Zourelidis C, et al. 1996. Effect of adenosine on the expression of beta 2-integrins and 1-selectin of polymorphonuclear leukocytes in vitro. J. Leukoc. Biol. 59:671-82
55. Franco R, Ferre S, Agnati L, Torvinen M, Gines S, et al. 2000. Evidence for adenosine/dopamine receptor interactions: indications for heteromerization. Neuropsychopharmacology 23:850-59
56. Gines S, Hillion J, Torvinen M, Le Crom S, Casado V, et al. 2000. Dopamine D1 and adenosine A1 receptors form functionally interacting heteromeric complexes. Proc. Natl. Acad. Sci. USA 97: 8606-11
57. 2A/dopamine D2 and adenosine A1/dopamine D1 receptor interactions in the basal ganglia. Brain Res. Brain Res. Rev. 26:258-73
58. Linden J, Thai T, Figler H, Robeva AS. 1999. Characterization of human A2B adenosine receptors: radioligand binding, western blotting and coupling to Gq in HEK-293 and HMC-1 mast cells. Mol. Pharmacol. 56:705-13
59. Cronstein BN, Kramer SB, Rosenstein ED, Korchak HM, Weissmann G, Hirschorn R. 1988. Occupancy of adenosine receptors raises cyclic AMP alone and in synergy with occupancy of chemoattractant receptors and inhibits membrane depolarization. Biochem. J. 252:709-15
60. Thiel M, Bardenheuer H, Poch G, Madel C, Peter K. 1991. Pentoxifylline does not act via adenosine receptors in the inhibition of the superoxide anion production of human polymorphonuclear leukocytes. Biochem. Biophys. Res. Commun. 180:53-58
61. Sullivan GW, Rieger JM, Scheld WM, Macdonald TL, Linden J. 2001. Cyclic AMP-dependent inhibition of human neutrophil oxidative activity by substituted 2-propynylcyclohexyl adenosine A(2A) receptor agonists. Br. J. Pharmacol. 132: 1017-26
62. Kull B, Svenningsson P, Fredholm BB. 2000. Adenosine A(2A) receptors are colocalized with and activate g(olf) in rat striarum. Mol. Pharmacol. 58:771-77
63. Fredholm BB, Arslan G, Halldner L, Kull B, Schulte G, Wasserman W. 2000. Structure and function of adenosine receptors and their genes. Naunyn Schmiedebergs Arch. Pharmacol. 362:364-74
64. 2A-adenosine receptor in primary human endothelial cells. J. Biol. Chem. 272:5792-99
65. Seidel MG, Klinger M, Freissmuth M, Holler C. 1999. Activation of mitogen-activated protein kinase by the A(2A)-adenosine receptor via a rap1-dependent and via a p21(ras)-dependent pathway. J. Biol. Chem. 274:25833-41
66. 2A receptor monoclonal antibodies. Mol. Pharmacol. 55:614-24
67. Lukashev DE, Smith PT, Caldwell CC, Ohta A, Apasov SG, Sitkovsky MV. 2003. Analysis of A2a receptor-deficient mice reveals no significant compensatory increases in the expression of A2b, A1, and A3 adenosine receptors in lymphoid organs. Biochem. Pharmacol. 65:2081-90
68. Witko-Sarsat V, Rieu P, Descamps-Latscha B, Lesavre P, Halbwachs-Mecarelli L. 2000. Neutrophils: molecules, functions and pathophysiological aspects. Lab. Invest. 80:617-53
69. Nathan C, Srimal S, Farber C, Sanchez E, Kabbash L, et al. 1989. Cytokine induced respiratory burst of human neutrophils: dependence on extracellular matrix proteins and cd11/cd18 integrins. J. Cell Biol. 109:1341-49
70. Arfors KE, Lundberg C, Lindbom L, Lundberg K, Beatty PG, Harlan JM. 1987. A monoclonal antibody to the membrane glycoprotein complex CD18 inhibits polymorphonuclear leukocyte accumulation and plasma leakage in vivo. Blood 69:338-40
71. Pearson JD, Gordon JL. 1985. Nucleotide metabolism by endothelium. Annu. Rev. Physiol. 47:617-27
72. Newby AC, Holmquist CA. 1981. Adenosine production inside rat polymorphonuclear leucocytes. Biochem. J. 200:399-403
73. Cronstein BN, Levin RI, Belanoff J, Weissmann G, Hirschhorn R. 1986. Adenosine: an endogenous inhibitor of neutrophil-mediated injury to endothelial cells. J. Clin. Invest. 78:760-70
74. Cronstein BN, Levin RI, Philips M, Hirschhorn R, Abramson SB, Weissmann G. 1992. Neutrophil adherence to endothelium is enhanced via adenosine A1 receptors and inhibited via adenosine A2 receptors. J. Immunol. 148:2201-6
75. Cronstein BN, Rosenstein ED, Kramer SB, Weissman G, Hirschhorn R. 1985. Adenosine: a physiologic modulator of superoxide anion generation by human neutrophils. Adenosine acts via an A2 receptor on human neutrophils. J. Immunol. 2:1366-71
76. Richter J. 1992. Effect of adenosine analogues and cAMP-raising agents on TNF, GM-CSF-, and chemotactic peptide-induced degranulation in single adherent neutrophils. J. Leukoc. Biol. 51:270-75
77. Thiel M, Chouker A. 1995. Acting via A2 receptors, adenosine inhibits the production of tumor necrosis factor-alpha of endotoxin-stimulated human polymorphonuclear leukocytes. J. Lab. Clin. Med. 124:275-82
78. Gessi S, Varani K, Merighi S, Cattabriga E, Iannotta V, Leung E, et al. 2002. A(3) adenosine receptors in human neutrophils and promyelocytic HL60 cells: a pharmacological and biochemical study. Mol. Pharmacol. 61:415-24
79. Cronstein B, Daguma L, Nichols D, Hutchison A, Williams M. 1990. The adenosine/neutrophil paradox resolved: human neutrophils possess both A1 and A2 receptors that promote chemotaxis and inhibit O2 generation, respectively. J. Clin. Invest. 85:1150-57
80. Sullivan GW, Linden J, Hewlett EL, Carper HT, Hylton JB, Mandell GL. 1990. Adenosine and related compounds counteract tumor necrosis factor-alpha inhibition of neutrophil migration: implications of a novel cyclic amp-independent action on the cell surface. J. Immunol. 145:1537-44
81. 2) release by activated human neutrophils. Clin. Immunol. Immunopathol. 42:76-85
82. Zalavary S, Bengtsson T. 1998. Modulation of the chemotactic peptide- and immunoglobulin G-triggered respiratory burst in human neutrophils by exogenous and endgenous adenosine. Eur. J. Pharmacol. 354:215-25
83. Thiel M, Holzer K, Kreimeier U, Mortiz S, Peter K, Messmer K. 1997. Effects of adenosine on the functions of circulating polymorphonuclear leukocytes during hyperdynamic endotoxemia. Infect. Immun. 65:2136-44
84. Smail EH, Cronstein BN, Meshulam T, Esposito AL, Ruggeri RW, Diamond RD. 1992. In vitro, Candida albicans releases the immune modulator adenosine and a second, high-molecular weight agent that blocks neutrophil killing. J. Immunol. 148:3588-95
85. Fearon DT, Locksley RM. 1996. The instructive role of innate immunity in the acquired immune response. Science 272:50-54
86. Broussas M, Cornillet-Lefebvre P, Potron G, Nguyen P. 1999. Inhibition of fMLP-triggered respiratory burst of human monocytes by adenosine: involvement of A3 adenosine receptor. J. Leukoc. Biol. 66:495-501
87. Sajjadi FG, Takabayashi K, Foster AC, Domingo RC, Firestein GS. 1996. Inhibition of TNF-α expression by adenosine. Role of A3 adenosine receptors. J. Immunol. 156:3435-42
88. Khoa ND, Montesinos MC, Reiss AB, Delano D, Awadallah N, Cronstein BN. 2001. Inflammatory cytokines regulate function and expression of adenosine A(2A) receptors in human monocytic THP-1 cells. J. Immunol. 167:4026-32
89. Xaus J, Mirabet M, Lloberas J, Soler C, Lluis C, et al. 1999. IFN-gamma upregulates the A(2B) adenosine receptor expression in macrophages: a mechanism of macrophage deactivation. J. Immunol. 162:3607-14
90. Panther E, Idzko M, Herouy Y, Rheinen H, Gebicke-Haerter PJ, et al. 2001. Expression and function of adenosine receptors in human dendritic cells. FASEB J. 15:1963-70
91. Kambayashi T, Wallin RP, Ljunggren HG. 2001. cAMP-elevating agents suppress dendritic cell function. J. Leukoc. Biol. 70:903-10
92. Panther E, Corinti S, Idzko M, Herouy Y, Napp M, et al. 2003. Adenosine affects expression of membrane molecules, cytokine and chemokine release, and the T-cell stimulatory capacity of human dendritic cells. Blood 101:3985-90
93. Huang S, Koshiba M, Apasov S, Sitkovsky M. 1997. Role of A2a adenosine receptor-mediated signaling in inhibition of T cell activation and expansion. Blood 90:1600-10
94. Hale LP, Braun RD, Gwinn WM, Greer PK, Dewhirst MW. 2002. Hypoxia in the thymus: role of oxygen tension in thymocyte survival. Am. J. Physiol. Heart Circ. Physiol. 282:H1467-77
95. 2A receptor-unrelated lymphotoxicity. Br. J. Pharmacol. 131:43-50
96. Apasov SG, Sitkovsky MV. 1999. The extracellular versus intracellular mechanisms of inhibition of TCR-triggered activation in thymocytes by adenosine under conditions of inhibited adenosine deaminase. Int. Immunol. 11:179-89
97. Aldrich MB, Blackburn MR, Datta SK, Kellems RE. 2000. Adenosine deaminase-deficient mice: models for the study of lymphocyte development and adenosine signaling. Adv. Exp. Med. Biol. 486:57-63
98. Apasov SG, Koshiba M, Chused TM, Sitkovsky MV. 1997. Effects of extracellular ATP and adenosine on different thymocyte subsets: possible role of ATP-gated channels and G protein-coupled purinergic receptors. J. Immunol. 158:5095-105
99. Apasov S, Chen JF, Smith P, Sitkovsky MV. 2000. A(2A) receptor-dependent and A(2A) receptor-independent effects of extracellular adenosine on murine thymocytes in conditions of adenosine deaminase deficiency. Blood 95:3859-67
100. Apasov SG, Blackburn MR, Kellems RE, Smith PT, Sitkovsky MV. 2001. Adenosine deaminase deficiency increases thymic apoptosis and causes defective T cell receptor signaling. J. Clin. Invest. 108:131-41
101. Koshiba M, Kojima H, Huang S, Apasov S, Sitkovsky MV. 1997. Memory of extracellular adenosine/A2a purinergic receptor-mediated signalling in murine T cells. J. Biol. Chem. 272:25881-89
102. 2A receptor gene-deficient mice. Biochem. J. 354:123-30
103. Yoneyama Y, Sawa R, Suzuki S, Yoneyama K, Doi D, Araki T. 2002. Relationship between adenosine deaminase activity and cytokine-secreting T cells in normal pregnancy. Obstet. Gynecol. 100:754-58
104. Yoneyama Y, Suzuki S, Sawa R, Otsubo Y, Power GG, Araki T. 2000. Plasma adenosine levels increase in women with normal pregnancies. Am. J. Obstet. Gynecol. 182:1200-3
105. Bonnafous JC, Dornand J, Favero J, Mani JC. 1981. Lymphocyte membrane adenosine receptors coupled to adenylate cyclase: properties and occurrence in various lymphocyte subclasses. J. Recept. Res. 2:347-66
106. Pastan IH, Johnson GS, Anderson J. 1975. Role of cyclic nucleotides in growth control. Annu. Rev. Immunol. 44:491-522
107. Holte H, Torjesen P, Blomhoff HK, Ruud E, Funderud S, Smeland EB. 1988. Cyclic AMP has the ability to influence multiple events during B cell stimulation. Eur. J. Immunol. 18:1359-66
108. Ledent C, Vaugeois JM, Schiffmann SN, Pedrazzini T, El Yacoubi M, et al. 1997. Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2a receptor. Nature 388:674-78
109. 2A receptor in mouse brain using the selective antagonist [3H]SCH 58261. Eur. J. Neurosci. 14:1567-70
110. 2A adenosine receptor deficiency attenuates brain injury induced by transient focal ischemia in mice. J. Neurosci. 19:9192-9200
111. 2A knockout mice. Stroke 34:739-44
112. Jacobson KA, Gao Z-G, Chen A, Barak D, Kim S, et al. 2001. Neoceptor concept based on molecular complementarity in GPCRs: a mutant adenosine A(3) receptor with selectively enhanced affinity for amine-modified nucleosides. J. Med. Chem. 44:4125-36
113. 2A adenosine receptors: high-affinity agonist binding to receptor-G protein complexes containing Gbeta(4). Mol. Pharmacol. 61:455-62
114. Baraldi PG, Cacciari B, Moro S, Spalluto G, Pastorin G, et al. 2002. Synthesis, biological activity, and molecular modeling investigation of new pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives as human A(3) adenosine receptor antagonists. J. Med. Chem. 45:770-80
115. Cassada DC, Tribble CG, Kaza AK, Fiser SM, Long SM, et al. 2001. Adenosine analogue reduces spinal cord reperfusion injury in a time-dependent fashion. Surgery 130:230-35
116. Firestein GS, Boyle D, Bullough DA, Gruber HE, Sajjadi FG, et al. 1994. Protective effect of an adenosine kinase inhibitor in septic shock. J. Immunol. 152: 5853-59
117. Cronstein BN, Naime D, Ostad E. 1993. The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J. Clin. Invest. 92:2675-82
118. Schijns VE. 2001. Induction and direction of immune responses by vaccine adjuvants. Crit. Rev. Immunol. 21:75-85
119. Chambers CA, Kuhns MS, Egen JG, Allison JP. 2001. CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu. Rev. Immunol. 19:565-94
120. Newby AC. 1984. Adenosine and the concept of retaliatory metabolites. Trends Biochem. Sci. 2:42-44